Live price temporarily unavailable.
Elicio Therapeutics (ELTX) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $2.88M | $28.3M | $2.30M | — | — | — |
| Growth (year over year) | — | +883.1% | −91.9% | — | — | — |
| Gross profit | $1.69M | $27.9M | $2.30M | — | — | — |
| Gross margin | 58.7% | 98.5% | 100.0% | — | — | — |
| Operating income | −$55.3M | −$39.3M | −$23.7M | −$35.7M | −$45.0M | −$37.7M |
| Operating margin | −1919.2% | −138.8% | −1031.4% | — | — | — |
| Net income | −$80.1M | −$54.6M | −$28.2M | −$35.2M | −$51.9M | −$39.6M |
| Net margin | −2781.5% | −192.8% | −1225.9% | — | — | — |
| EPS (diluted) | −$5.43 | −$1.93 | −$89.27 | −$6.96 | −$4.25 | −$2.58 |
| Balance sheet | ||||||
| Cash and equivalents | $34.6M | $88.8M | $6.16M | $12.9M | $17.6M | $18.6M |
| Total assets | $47.3M | $96.5M | $22.7M | $27.1M | $28.2M | $25.9M |
| Total liabilities | $137.8M | $15.0M | $13.7M | $15.8M | $39.5M | $24.2M |
| Long-term debt | $635.0K | $0 | — | — | $20.0M | $9.41M |
| Shareholders' equity | −$90.4M | −$74.5M | −$102.1M | $11.4M | −$11.3M | $1.64M |
| Cash flow | ||||||
| Operating cash flow | −$22.9M | −$52.6M | −$22.2M | −$32.7M | −$37.1M | −$37.0M |
| Capital expenditure | $41.0K | $382.0K | $654.0K | $66.0K | $87.0K | $16.0K |
| Free cash flow | −$22.9M | −$53.0M | −$22.8M | −$32.8M | −$37.2M | −$37.0M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$10.3M | −$13.5M | −$10.7M | −$10.1M | −$8.04M | −$8.84M | −$10.6M | −$10.4M |
| Net income | −$18.8M | −$14.0M | −$11.2M | −$10.6M | −$10.1M | −$7.72M | −$11.8M | −$8.22M |
| EPS (diluted) | −$1.39 | −$1.07 | −$0.87 | −$0.66 | −$0.60 | −$0.45 | −$0.65 | −$0.43 |
| Balance sheet | ||||||||
| Cash and equivalents | $26.0M | $17.6M | $18.4M | $22.1M | $20.6M | $18.6M | $14.9M | $23.5M |
| Total assets | $38.4M | $28.2M | $28.1M | $29.5M | $28.3M | $25.9M | $22.7M | $31.3M |
| Total liabilities | $57.4M | $39.5M | $19.2M | $27.7M | $24.5M | $24.2M | $24.1M | $23.4M |
| Long-term debt | — | $20.0M | — | $9.34M | $9.72M | $9.41M | $9.47M | $9.54M |
| Shareholders' equity | −$19.0M | −$11.3M | $8.90M | $1.83M | $3.82M | $1.64M | −$1.44M | $7.94M |
| Cash flow | ||||||||
| Operating cash flow | −$7.27M | −$8.74M | −$10.1M | −$8.95M | −$11.1M | −$6.80M | −$11.6M | −$8.16M |
| Capital expenditure | $0 | $45.0K | — | — | $0 | $16.0K | — | — |
| Free cash flow | −$7.27M | −$8.79M | — | — | −$11.1M | −$6.81M | — | — |
From Elicio Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Elicio Therapeutics in our feed yet.